119 related articles for article (PubMed ID: 19026643)
1. HSP90 is required for TAK1 stability but not for its activation in the pro-inflammatory signaling pathway.
Liu XY; Seh CC; Cheung PC
FEBS Lett; 2008 Dec; 582(29):4023-31. PubMed ID: 19026643
[TBL] [Abstract][Full Text] [Related]
2. Heat shock protein 90 (Hsp90) regulates the stability of transforming growth factor beta-activated kinase 1 (TAK1) in interleukin-1beta-induced cell signaling.
Shi L; Zhang Z; Fang S; Xu J; Liu J; Shen J; Fang F; Luo L; Yin Z
Mol Immunol; 2009 Feb; 46(4):541-50. PubMed ID: 18950863
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
4. Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte.
Ota A; Zhang J; Ping P; Han J; Wang Y
Circ Res; 2010 Apr; 106(8):1404-12. PubMed ID: 20299663
[TBL] [Abstract][Full Text] [Related]
5. Geldanamycin interferes with the 90-kDa heat shock protein, affecting lipopolysaccharide-mediated interleukin-1 expression and apoptosis within macrophages.
Hsu HY; Wu HL; Tan SK; Li VP; Wang WT; Hsu J; Cheng CH
Mol Pharmacol; 2007 Jan; 71(1):344-56. PubMed ID: 16868182
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
Madrigal-Matute J; López-Franco O; Blanco-Colio LM; Muñoz-García B; Ramos-Mozo P; Ortega L; Egido J; Martín-Ventura JL
Cardiovasc Res; 2010 May; 86(2):330-7. PubMed ID: 20154064
[TBL] [Abstract][Full Text] [Related]
7. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
8. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
[TBL] [Abstract][Full Text] [Related]
9. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.
Nony P; Gaude H; Rossel M; Fournier L; Rouault JP; Billaud M
Oncogene; 2003 Dec; 22(57):9165-75. PubMed ID: 14668798
[TBL] [Abstract][Full Text] [Related]
10. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.
Dello Russo C; Polak PE; Mercado PR; Spagnolo A; Sharp A; Murphy P; Kamal A; Burrows FJ; Fritz LC; Feinstein DL
J Neurochem; 2006 Dec; 99(5):1351-62. PubMed ID: 17064348
[TBL] [Abstract][Full Text] [Related]
11. Stercurensin inhibits nuclear factor-κB-dependent inflammatory signals through attenuation of TAK1-TAB1 complex formation.
Kim YJ; Kim HC; Ko H; Amor EC; Lee JW; Yang HO
J Cell Biochem; 2011 Feb; 112(2):548-58. PubMed ID: 21268076
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells.
Fang S; Fu J; Yuan X; Han C; Shi L; Xin Y; Luo L; Yin Z
Cell Immunol; 2009; 259(1):49-55. PubMed ID: 19560753
[TBL] [Abstract][Full Text] [Related]
13. TAB3, a new binding partner of the protein kinase TAK1.
Cheung PC; Nebreda AR; Cohen P
Biochem J; 2004 Feb; 378(Pt 1):27-34. PubMed ID: 14670075
[TBL] [Abstract][Full Text] [Related]
14. Cdk2: a genuine protein kinase client of Hsp90 and Cdc37.
Prince T; Sun L; Matts RL
Biochemistry; 2005 Nov; 44(46):15287-95. PubMed ID: 16285732
[TBL] [Abstract][Full Text] [Related]
15. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
[TBL] [Abstract][Full Text] [Related]
16. The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.
Schnaider T; Somogyi J; Csermely P; Szamel M
Cell Stress Chaperones; 2000 Jan; 5(1):52-61. PubMed ID: 10701840
[TBL] [Abstract][Full Text] [Related]
17. Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling.
Zhang H; Wu W; Du Y; Santos SJ; Conrad SE; Watson JT; Grammatikakis N; Gallo KA
J Biol Chem; 2004 May; 279(19):19457-63. PubMed ID: 15001580
[TBL] [Abstract][Full Text] [Related]
18. L347P PINK1 mutant that fails to bind to Hsp90/Cdc37 chaperones is rapidly degraded in a proteasome-dependent manner.
Moriwaki Y; Kim YJ; Ido Y; Misawa H; Kawashima K; Endo S; Takahashi R
Neurosci Res; 2008 May; 61(1):43-8. PubMed ID: 18359116
[TBL] [Abstract][Full Text] [Related]
19. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
Kurashina R; Ohyashiki JH; Kobayashi C; Hamamura R; Zhang Y; Hirano T; Ohyashiki K
Cancer Lett; 2009 Oct; 284(1):62-70. PubMed ID: 19464103
[TBL] [Abstract][Full Text] [Related]
20. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
